Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial

被引：0
|
作者：
Zahra Darabi
Mina Darand
Zahra Yari
Mehdi Hedayati
Amirhosein Faghihi
Shahram Agah
Azita Hekmatdoost
机构：
[1] Shahid Beheshti University of Medical Sciences,Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute
[2] Shahid Beheshti University of Medical Sciences,Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences
[3] Iran University of Medical Sciences,Colorectal Research Center
来源：
BMC Research Notes | / 12卷
关键词：
Citrulline; NAFLD; Fatty liver; Inflammation; NASH;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial
    Milad Daneshi-Maskooni
    Seyed Ali Keshavarz
    Mostafa Qorbani
    Siavash Mansouri
    Seyed Moayed Alavian
    Mahtab Badri-Fariman
    Seyed Ali Jazayeri-Tehrani
    Gity Sotoudeh
    BMC Complementary and Alternative Medicine, 19
  • [42] The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study
    Faghihzadeh, Forouzan
    Adibi, Payman
    Hekmatdoost, Azita
    BRITISH JOURNAL OF NUTRITION, 2015, 114 (05) : 796 - 803
  • [43] A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial
    Hariri, Mitra
    Gholami, Ali
    Mirhafez, Seyed Reza
    Bidkhori, Mohammad
    Sahebkar, Amirhosein
    COMPLEMENTARY THERAPIES IN MEDICINE, 2020, 51
  • [44] Effects of sumac (Rhus coriaria) on lipid profile, leptin and steatosis in patients with non-alcoholic fatty liver disease: A randomized double-blind placebo-controlled trial
    Ehsani, Simin
    Zolfaghari, Hamid
    Kazemi, Samira
    Shidfar, Farzad
    JOURNAL OF HERBAL MEDICINE, 2022, 31
  • [45] A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
    Saeed Chashmniam
    Seyed Reza Mirhafez
    Maryam Dehabeh
    Mitra Hariri
    Mohsen Azimi Nezhad
    B. Fatemeh Nobakht M. Gh
    European Journal of Clinical Nutrition, 2019, 73 : 1224 - 1235
  • [46] A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
    Chashmniam, Saeed
    Mirhafez, Seyed Reza
    Dehabeh, Maryam
    Hariri, Mitra
    Nezhad, Mohsen Azimi
    Nobakht, B. Fatemeh M. Gh
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2019, 73 (09) : 1224 - 1235
  • [47] Assessing the clinical and biochemical efficacy of alpha-lipoic acid in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled clinical trial
    Ebrahimi-Mameghani, Mehrangiz
    Asghari, Somayyeh
    Naeini, Fatemeh
    Taghizadeh, Mahdiyeh
    Hamedi-Shahraki, Soudabeh
    Amirkhizi, Farshad
    JOURNAL OF FUNCTIONAL FOODS, 2024, 114
  • [48] Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial
    Qian Huang
    Ziming An
    Xin Xin
    Qinmei Sun
    Siting Gao
    Sheng Lv
    Xiao Xu
    Shuohui Yang
    Fang Lu
    Jie Yuan
    Yu Zhao
    Yiyang Hu
    Ping Liu
    Qin Feng
    BMC Complementary Medicine and Therapies, 23
  • [49] Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial
    Huang, Qian
    An, Ziming
    Xin, Xin
    Sun, Qinmei
    Gao, Siting
    Lv, Sheng
    Xu, Xiao
    Yang, Shuohui
    Lu, Fang
    Yuan, Jie
    Zhao, Yu
    Hu, Yiyang
    Liu, Ping
    Feng, Qin
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2023, 23 (01)
  • [50] A PHASE-2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF ARAMCHOL FOR THE TREATMENT OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Safadi, R.
    Konikoff, F. M.
    Oren, R.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S558 - S558
12345